Horizons in Hemophilia, March 2011
NHF Washington Days
Eleven people representing Georgia's bleeding disorder community traveled to Washington, DC. February 16 - 18 for the National Hemophilia Foundation's annual lobbying days. Justin, Mary Beth, Chip, Tammi, TJ, Les, and Najla joined Hemophilia of Georgia staffers Trish Dominic, Vic McCarty, Michelle Fitzwater, and Jeff Cornett to meet with our state's senators and representatives. Hundreds of people from bleeding disorder organizations across the country came to Washington to speak out in support of the Affordable Care Act (health care reform) and to defend funding for hemophilia treatment centers. Read more.
World Hemophilia Day
The World Hemophilia Federation has designated April 17 as World Hemophilia Day. The theme this year is “be inspired, get involved in treatment for all.” Read more.
State Advocacy Update
The Georgia General Assembly is considering legislation that will directly affect the bleeding disorders community. This legislation includes the state budget and the Hemophilia Advisory Board Act (HB 378). Read more.
Two Trot to Clot Fundraising Events this Spring
Hemophilia of Georgia will host the Trot to Clot Walk on Saturday April 16, 2011 at East Cobb Park in Marietta, Georgia and the Trot to Clot Walk/Run on May 21, 2011 at Stone Mountain Park. These events will raise money to fund programs and activities for people who have hemophilia, von Willebrand Disease, and other inherited bleeding disorders. Read more.
Hemophilia of Georgia to Host Annual Volunteer Reception
Volunteers play a vital role in the overall success of Hemophilia of Georgia. We are pleased to announce plans for the annual volunteer reception to honor all volunteers who served the organization in 2010. The volunteer reception will be held at 5:30 p.m. on Tuesday April 12, 2011 at The Roswell Mill Club. Read more.
Corifact Approved by FDA for Treatment of Factor XIII Deficiency
CSL Behring announced that the FDA has granted approval for Corifact, factor XIII concentrate (human), for the routine prophylactic treatment of congenital factor XIII deficiency. The product has been available in 12 countries under the trade name Fibrogammin-P. Read more.
MASAC Recommendation On Use Of Emergency Medical Identification Devices For Children
The following recommendations were approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on November 13, 2010, and adopted by the NHF Board of Directors on November 14, 2010. The Nursing Working Group conducted a survey of use of Emergency Medical Identification (EMI) devices available for children and found that there are no devices appropriate for infants and young children under 3 years of age. Read more.
Study Shows Positive Outcomes for Early Prophylaxis in Children
A group of European researchers published a study in January 2011 affirming that prophylactic, or preventive, treatment of children with hemophilia A, particularly when initiated at an early age (at or before 36 months), can prevent bleeds and joint disease. Read more.
Support Hemophilia of Georgia through Matching Gifts
Individual donors can increase the value of their contributions by simply participating in a matching program through their employer. In some cases, the corporations match every dollar the individual donates. Read more.
Client Dinner Photos
View the clinic schedules for the Georgia Hemophilia Treatment Centers.
Hemophilia of Georgia is not engaged in the practice of medicine and does not endorse or support any particular factor concentrate or treatment protocol. HoG recommends that you consult with your physician prior to starting any course of therapy. Occasionally HoG disseminates information on new treatments or therapies. HoG shares this for informational purposes only and makes no claim as to its accuracy or effectiveness.